June, 2006
Clinical Studies – Geographic Distribution
• In the world: + 15.000 clinical studies in progress
– Applied Clinical Trials, April 2003
• Number of global studies increased 11.7% from
March 2004 to March 2005
- Applied Clinical Trials, June 2006
Clinical Studies in U.S.A.
• 32.240 clinical studies are listed in the
ClinicalTrials.gov
• 20.463 clinical studies in U.S.A. are, at this
moment, in planning or in opening phase
• 9.594 clinical studies in U.S.A. are, at this
moment, enrolling patients
• 491clinical studies in South America are enrolling
patients
ClinicalTrials.gov 16 August 2006
Increasing Demand
• More than 600 new drugs for treatment of
cancer are in development this year.
• More than 650 clinical studies are in
progress for breast, lung and prostate
cancer
• 238.000 patients are necessary to
complete those studies
Clinical Trials for Cancer Running Out of
Volunteers, CenterWatch, July 2006
ANVISA
Special communication (CEs)
767
1000
900
767
800
846 880 819 881
940
394 430
700
600
500
180 394
400
30
300
200
30
100
430
80
180
80
0
1
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
!
"
#
!
"
#
$% &
(
+
#
$
'
&&
) * +
(
'
&
,
-
(./
&
) 0
&
!
"
(.
1 ! "
32
- (
&
"
+
) * + 0 (0 .6
) 02
- "! 2
!
41
,
+
(
,
1
0
0
+
!
&
+
(
1 8
+ )0 0
) 0
•
•
•
•
(
+"'
51 ! " 0
/ &
71 !
+
,
"
&
&
(
.
.
&
1
0 +
0$
8
8
!
!
6
.
) (
"´
(
)
!
"9
'
1. Central feasibility and enrollment projections
2. Central study initiation services
3. Contracts and proposals
4. Regulatory documents
5. Drug importation and distribution
6. Harmonized IBPC SOPs and training (SOP and protocolspecific)
7. Common technology platform and study management
systems
8. Patient data base
!
"9!
(
) *
%
&
1
!
": !
,
51
!
":
,
+
1
"
%
+
1
'
1
#
(&
51
71
1
&
;++
(1
'
&&
(
"
! '
(
1
'
•
"
•
!
(
&
+
•
&
!
8 '
;'
(
•
- (
(
•
8
) *
"
(
,
0 !
1
1
<=81
&
. '
( ,.'
! '
+
) 0 0
1
&
1
-'
' )$ -
(."
PRIMARY LOCATION
Estimated New Cases per year
NEOPLASIAS
Male
Female
Total
-
48,930
48,930
Lung
17,850
9,320
27,170
Stomach
14,970
8,230
23,200
-
19,260
19,260
Prostate
47,280
-
47,280
Colorectal
11,390
13,970
25,360
Esophagus
7,970
2,610
10,580
Leukemia
5,330
4,220
9,550
Oral Cavity
10,060
3,410
13,470
Melanoma
2,710
3,050
5,760
Other Locations
61,530
63,320
124,850
179,090
176,320
355,410
55,480
61,160
116,640
234,570
237,480
472,050
Breast
Cervix
Subtotal
Skin
ALL NEOPLASIAS
$!
>
"?
–"
;
3.
5
4@
0 &$ )))1
1( '1, A
!
1
51
"9-
-
&
&
$#
'
& , 0
. +/
&
09B
)0
/
0!
!
3.
")
&
5
4@
0 &$ &
1
1
1( ' , A
!
"
&
(
"!%!;
!%;
!> %!%C%!->
>
/
E
"
(
8
"
-
/
'
&
D
8
!
(
(
&
7
-
C '
/
/
&
(
E
&
D
"
(
&
8
(
#
&
/
#
,
"
I
/
(
( F
"
/
-
H
I
; #
/" C
!
G
,
8 (
D
"
8
/
&
/
&
&
J
"
#
8
"
' 0
"
5
,
!
K!
"
":
' 0
,
(
&
8 (
& &0
G
(
!
"9
&
#
+
3
'
/
,4
Multicentric Phase III
13
Phase II
8
Phase I/II
2
Phase II/III
1
Phase IV
3
Multicentric Phase III
3
Phase II
2
Phase IV
3
Multicentric Phase III
7
Phase II/III
1
Phase I
1
*
3E
%
3
4
)
/
4
!
"9;
.
&
+ !: "J
,
*
$
C '
#
$
#
-
#
8
&
E
!>"8 9 !
(.
"
"
9
>
"?
+
$
-
(
"
8
&
.+
*
$
$
#
"
#
C '
(. /
+
8
#
C '
/
. +
(. -
-
#
(.
&
(
0
+
.'
!
.'
(.9
C 8
$
-
(
"
8
(.
-
E
"
"M
(
. +"
;
#
L
. +"
"M
(
-
(.
#
!
"
0
&
: '
Gastrointestinal and Other malignances
Incidence of new cases by site in 2005
CID-1O 2nd. editionCity
New cancer cases per site by topography
Total
Salvador Fortaleza BH1
BH2
P. Alegre Ja
1
1
1
1
1
1
C15Esophagus
C16Stomach
C18Colon
C20Rectum
C22Hepatocarcinoma
C25Pancreas
C28Anal Canal
8
70
245
40
55
140
1
23
13
18
34
2
1
15
225
156
145
121
108
64
49
59
8
9
15
190
131
112
92
108
260
174
98
13
57
4
Other malignances
C34Bronchial tubes and Lungs
C43Melanoma
C44Skin
C50Breast
C53Cervix
C56Ovary
C61Prostate
139
22
30
417
32
69
317
159
105
75
24
139
226
57
# of Sites
S‹o Paulo Piracicaba
Limeira
1
1
1
9
6
24
42
24
2
8
4
8
8
36
24
872
2,592
5,226
1,593
392
408
287
86
10
44
142
18
28
106
12
182
30
6
88
GI malignances
564
302
25
131
27
14
908
217
62
115
83
481
93
40
166
20
12
196
1,866
4,405
1,101
312
140
220
270
6
2
822
1,124
5,344 504 6,070
102
342
210
21
58
732
1,525 612
836
1,104
1,030
1,293
14,612
1,346
1,041
3,896
- (
(
+!
"
!
!
E
8 '
"
.
>
3 ! +
"
0
> ) *
4
0B
";-
<=8
!%
&&
"
-++
!
0
B (
&
,
- (
(
+!
"
-
&
-
!
!
E
8 '
%
"
.
>
3 ! +
"
0
> ) *
4
0B
";-
<=8
!%
&&
"
-++
!
0
B (
&
,
!
"9
0
/ ++
0
D
(
D
/
8
+
"
I " ,
N#
,
(
0
/
' 0
"
&
/
&
/
&
D
D
"1 D
"; ->
;.
8
N"
8
N#
"
D
(
8 (
8 (
(
?
(
/
/
/
#
/
8
>
(
8
E
H&
C>!E;
9/
&
I
I
C>!E;
9/
&
I
I
!
8
9/
J
&
/
!
"
"M
"
0
E
C"
-
E#C
#
N
&
(
8 (
E
"
*
-
"
E
%
(
,
C '
#E
I
-
>'
(
!
I D
/
/ *
F
"
#
>
D,
!
DE
,
M
"
D (
-
&
,
&
( F
8
"
' 0
I
I
"
&
'
' 0
G
!
"
1
!
8 '
"0
•
$
0B
B
51
#
•
+
,
/
#!%
$
0B
+ 0.
#!% > ,
0&
0
(
#1B1
D
E
+
•
#
•
"
•
/
•
";-
1
!
71
.
* 0
+
+
";- + "
0
,
+ 0
0
-
(
/
&
í
D,
F
!
" 9 <8
-
1
•
•
#
D'
51 - (
•
•
71
1
1
'
.+
++
'
(
,
&
' )
+
&
0
(
! '
&
&
0#
( ) 0
&
(
+
(+
&
-
&
EB8
>"!
!
"9
(
.
,
1 8
0 '
51 %)
1
&
)
&
'
51
71 "
1 #
1 ;
!
+
+
(!
7
+ 0
+&
&
,.
. ' )
&&
' 4
.
)
,
0. ' )
3+
+
+
,."->;
8>J! 8
(
( )0
'
.
!
"
B (
1 "
,
,
51 %
71
) 0
+ 5&
(
+
•
+
'
1 B '
1
8>J! 8
.
+
(&
(.
1
(
•
+
$
3
1 -&
,
&
'
8(
(
5
,
O0
6
.4
+
1
.
1
(.
+
+!
""
,
1. Accelerated study initiation and enrollment
2. Consistent research excellence, quality and compliance
(international standards; pivotal programs)
3. Sponsor performance and accountability
4. Patient and site management time and expense savings
5. Real time information and communication
6. Comprehensive and cost effective Latin American CRO
services
7. Contribution to national and international oncology
research capacity, expertise and patient care
June, 2006